Cannabosides – A Novel Class of Cannabinoid Prodrugs
Novel cannabinoid glycoside compositions of matter have reliably lead to dramatic improvements in drug solubility and stability, as evidenced below.
Patents are pending for more than 20 novel cannabinoid glycoside prodrugs (including prodrug versions of of CBD, THC, CBDV, and more).
As federal restrictions on medical research in this field are beginning to relax, and as interest from the public continues to mount, there is a striking increase in the number of clinical trials being sponsored by academic investigators for use of cannabinoids to treat lucrative, large market disease indications. Given our ability to rapidly create proprietary prodrug versions of each these cannabinoids, we stand to benefit from emerging data, and increasing recognition from the medical community of the potent pain relief and anti-inflammatory effects of cannabinoids.